Target Audience — Hematologists-oncologists, oncologists, physician assistants, nurse practitioners, oncology nurses, and pharmacists, involved in the care of patients with myeloma.
|Learning Objectives — At the conclusion of this program, participants will be able to:|
|•||Describe the latest developments in myeloma, including diagnosis, current and emerging treatments|
|•||Engage patients and caregivers in clinical trial discussions on newly approved therapies and emerging therapies for myeloma|
|•||Identify strategies for optimal patient care|
|•||Apply evidence-based treatment strategies|
Jointly provided by The Leukemia & Lymphoma Society, Albert Einstein College of Medicine, and Medical Learning Institute, Inc.
This activity is supported by educational grants from AbbVie Inc., Amgen Inc., Celgene Corporation, and Takeda Oncology.
Continuing Education for Physicians, Pharmacists, Nurse Practitioners, and Nurses
Physician Credit Designation
Albert Einstein College of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|Pharmacy Credit Designation
The Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this application-based activity provides for 1.25 contact hours (0.125 CEUs) of continuing pharmacy education credit. The Universal Activity Number for this activity is 0468-9999-18-012-H01-P.
|Nurse Practitioner Credit Designation
This activity is approved for 1.25 contact hour(s) of continuing education (which includes X.XX hour(s) pharmacology) by the American Association of Nurse Practitioners. Activity ID# xxxxxxxx. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Registered Nursing Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.25 continuing education contact hours through the California Board of Registered Nursing.
Nurse Practitioner Credit Designation
This activity is approved for 1.25 contact hour(s) of continuing education (which includes 1.25 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 18093353. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Disclosure of Conflicts of Interest
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine, The Leukemia & Lymphoma Society (LLS), and Medical Learning Institute, Inc., requires that faculty participating in any CME/CE activity disclose to the audience any relevant relationship(s) with a pharmaceutical, product, or device company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present.
The Albert Einstein College of Medicine and LLS also require that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. Albert Einstein College of Medicine, CCME staff, LLS and Medical Learning Institute, Inc., have no conflicts of interest with commercial interests related directly or indirectly to this educational activity.
James E. Hoffman, MD, has disclosed he is on the Speaker’s Bureau for Celgene Corporation. He does not intend to reference unlabeled/unapproved uses of drugs or products in his presentation.
Edward A. Stadtmauer, MD, has disclosed he is a Consultant for Amgen, Celgene, Novartis and Takeda. He also has done research for AbbVie and Celgene. He does not intend to reference unlabeled/unapproved uses of drugs or products in his presentation.
Lauren Berger, MPH, presents no relevant conflict of interest. (Planner)
Christopher Gusack, presents no relevant conflict of interest. (Planner)
Loretta Fala, the Medical Writer/Editor for this activity, presents no relevant conflict of interest. (Planner)
Teresa Haile, RPh, MBA, Peer Reviewer presents no relevant conflict of interest. (CPE Peer Reviewer)
Victor B. Hatcher, Ph.D, Associate Dean and Professor of Medicine and Microbiology presents no relevant conflict of interest. (CME Reviewer)
Amit K. Verma, MD, Peer Reviewer presents no relevant conflict of interest. (Peer Reviewer)
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of LLS, Einstein or MLI. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of this CME/CE/CPE activity site, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.